Toxicology and pharmacokinetic study of orally administered 5-iodo-2-pyrimidinone-2′deoxyribose (IPdR) x 28 days in Fischer-344 rats: Impact on the initial clinical phase I trial design of IPdR-mediated radiosensitization

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 323-334

  Kinsella, Timothy J ^a   Kinsella, Michael T ^a   Hong, Seongwon ^b   Johnson, Jerry P ^b   Burback, Brian ^b   Tosca, Patricia J ^b  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

IPdR; PK; Radiosensitization; Toxicology

Indexed keywords

5 IODO 2 PYRIMIDINONE 2' DEOXYRIBOSE; ALKALINE PHOSPHATASE; GLOBULIN; HEMOGLOBIN; NSC 726188; PROTEIN; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATROPHY; AUTOPSY; BLOOD SAMPLING; BONE MARROW; CELL HYPERPLASIA; CELL VACUOLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; ERYTHROCYTE; FEMALE; FISCHER 344 RAT; HISTOPATHOLOGY; LEUKOCYTE; LIVER; LIVER CELL; LYMPH NODE; LYMPHOID TISSUE; MALE; MAXIMUM PLASMA CONCENTRATION; MICROSCOPY; MONITORING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOSENSITIZATION; RAT; SEX DIFFERENCE; SUBMANDIBULAR GLAND; THROMBOCYTE; THYMUS; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; BLOOD CELL COUNT; CLINICAL TRIALS, PHASE I AS TOPIC; FEMALE; HALF-LIFE; IDOXURIDINE; INTESTINAL ABSORPTION; MALE; PYRIMIDINE NUCLEOSIDES; RADIATION-SENSITIZING AGENTS; RATS; RATS, INBRED F344;

EID: 36348956696     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0518-4     Document Type: Article

References (26)

1. Berry SE, Kinsella TJ (2001) Targeting DNA mismatch repair for human tumor radiosensitization. Semin Radiat Oncol 11:300-315
2. Berry SE, Loh T, Yan T, Kinsella TJ (2003) Role of MutSalpha in the recognition of iododeoxyuridine in DNA. Cancer Res 63:5490-5495
3. Chang AE, Collins JM, Speth PA, Smith R, Rowland JB, Walton L, Begley MG, Glatstein E, Kinsella TJ (1989) A phase I study of intraarterial iododeoxyuridine in patients with colorectal liver metastases. J Clin Oncol 7:662-668
4. Chang CN, Doong SL, Cheng YC (1992) Conversion of 5-iodo-2-pyrimidinone- 2′-deoxyribose to 5-iodo-deoxyuridine by aldehyde oxidase. Implication in hepatotropic drug design. Biochem Pharmacol 43:2269-2273
5. Efange SM, Alessi EM, Shih HC, Cheng YC, Bardos TJ (1985) Synthesis and biological activities of 2-pyrimidinone nucleosides. 2. 5-Halo-2-pyrimidinone 2′-deoxyribonucleosides. J Med Chem 28:904-910
6. Kinsella TJ (1996) An approach to the radiosensitization of human tumors. Cancer J Sci Am:184-193
7. Kinsella TJ, Collins J, Rowland J, Klecker R Jr, Wright D, Katz D, Steinberg SM, Glastein E (1988) Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 6:871-879
8. Kinsella TJ, Kunugi KA, Vielhuber KA, McCulloch W, Liu SH, Cheng YC (1994) An in vivo comparison of oral 5-iodo-2′-deoxyuridine and 5-iodo-2-pyrimidinone-2′-deoxyribose toxicity, pharmacokinetics, and DNA incorporation in athymic mouse tissues and the human colon cancer xenograft, HCT-116. Cancer Res 54:2695-700
9. Kinsella TJ, Kunugi KA, Vielhuber KA, Potter DM, Fitzsimmons ME, Collins JM (1998) Preclinical evaluation of 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′-deoxyuridine-mediated radiosensitization in mouse and human tissues. Clin Cancer Res 4:99-109
10. Kinsella TJ, Schupp JE, Davis TW, Berry SE, Hwang HS, Warren K, Balis F, Barnett J, Sands H (2000) Preclinical study of the systemic toxicity and pharmacokinetics of 5-iodo-2-pyrimidinone-2′-deoxyribose as a radiosensitizing prodrug in two, non-rodent animal species: implications for phase I study design. Clin Cancer Res 6:3670-3679
11. Kinsella TJ, Vielhuber KA, Kunugi KA, Schupp J, Davis TW, Sands H (2000) Preclinical toxicity and efficacy study of a 14-day schedule of oral 5-iodo-2-pyrimidinone-2′-deoxyribose as a prodrug for 5-iodo-2′- deoxyuridine radiosensitization in U251 human glioblastoma xenografts. Clin Cancer Res 6:1468-1475
12. Lewandowski GA, Cheng YC (1991) Mechanism and mode of action of 5-iodo-2-pyrimidinone 2′-deoxyribonucleoside, a potent anti-herpes simplex virus compound, in herpes simplex virus-infected cells. Mol Pharmacol 39:27-33
13. McGinn CJ, Kunugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ, Kinsella TJ (1996) Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study. Clin Cancer Res 2:1299-1305
14. Rooseboom M, Commandeur JN, Vermeulen NP (2004) Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev 56:53-102
15. Schulz CA, Mehta MP, Badie B, McGinn CJ, Robins HI, Hayes L, Chappell R, Volkman J, Binger K, Arzoomanian R, Simon K, Alberti D, Feierabend C, Tutsch KD, Kunugi KA, Wilding G, Kinsella TJ (2004) Continuous 28-day iododeoxyuridine infusion and hyperfractionated accelerated radiotherapy for malignant glioma: a phase I clinical study. Int J Radiat Oncol Biol Phys 59:1107-1115
16. Seo Y, Yan T, Schupp JE, Colussi V, Taylor KL, Kinsella TJ (2004) Differential radiosensitization in DNA mismatch repair-proficient and -deficient human colon cancer xenografts with 5-iodo-2-pyrimidinone-2′-deoxyribose. Clin Cancer Res 10:7520-7528
17. Seo Y, Yan T, Schupp JE Radivoyevitch T, Kinsella TJ (2005) Schedule-dependent drug effects of oral 5-iodo-2-pyrimidinone-2′- deoxyribose as an in vivo radiosensitizer in U251 human glioblastoma xenografts. Clin Cancer Res 11:7499-7505
18. Sondak VK, Robertson JM, Sussman JJ, Saran PA, Chang AE, Lawrence TS (1998) Preoperative idoxuridine and radiation for large soft tissue sarcomas: clinical results with 5 year follow-up. Ann Surg Oncol 5:106-112
19. Speth PA, Kinsella TJ, Belanger K, Klecker RW Jr, Smith R, Rowland JB, Collins JM (1988) Fluorodeoxyuridine modulation of the incorporation of iododeoxyuridine into DNA of granulocytes: a phase I and clinical pharmacological study. Cancer Res 48:2933-2937
20. Sullivan FJ, Herscher LL, Cook JA, Smith J, Steinberg SM, Epstein AH, Oldfield EH, Goffman TE, Kinsella TJ, Mitchell JB, Glatstein E (1994) National Cancer Institute (phase II) study of high-grade glioma treated with accelerated hyperfractionated radiation and iododeoxyuridine: results in anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 30:583-590
21. Taverna P, Hwang HS, Schupp JE, Radivoyevitch T, Session NN, Reddy G, Zarling DA, Kinsella TJ (2003) Inhibition of base excision repair potentiates iododeoxyuridine-induced cytotoxicity and radiosensitization. Cancer Res 63:838-846
22. Turner DP, Cortellino S, Schupp JE, Caretti E, Loh T, Kinsella TJ, Bellacosa A (2006) The DNA N-glycosylase MED1 exhibits preference for halogenated pyrimidines and is involved in the cytotoxicity of 5-iododeoxyuridine. Cancer Res 66:7686-7693
23. Urtasun RC, Cosmatos D, DelRowe J, Kinsella TJ, Lester S, Wasserman T, Fulton DS (1993) Iododeoxyuridine (IUdR) combined with radiation in the treatment of malignant glioma: a comparison of short versus long intravenous dose schedules (RTOG 86-12). Int J Radiat Oncol Biol Phys 27:207-214
24. Urtasun RC, Kinsella TJ, Farnan N, DelRowe JD, Lester SG, Fulton DS (1996) Survival improvement in anaplastic astrocytoma, combining external radiation with halogenated pyrimidines: final report of RTOG 86-12, phase I-II study. [see comment]. Int J Radiat Oncol Biol Phys 36:1163-1167
25. Yan T, Seo Y, Schupp JE, Zeng X, Desai AB, Kinsella TJ (2006) Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther 5:893-902
26. Zarling DAV AK, Kinsella T (2004) New radiosensitizing (RS) regimens, drugs, prodrugs and candidates: Capecitabine, Gemcitabine, Fludarabine, IPdR, Avastin, Veglin, Gleevac, Radvac, Erbitux or Irressa. Clin Adv Hematol Oncol 2:793-805